Plain-English translation of NCT07689643 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-stage trial is testing a new radioactive medication called , given as an injection, combined with standard immune checkpoint inhibitor drugs (which help your immune system fight cancer). The study will track whether this combination is safe and how well it works in people with advanced non-small cell lung cancer whose tumors have a specific marker called FAP.
Advanced lung cancer is difficult to treat, and current options don't work for everyone. This medication is designed to deliver radiation directly to cancer cells while the immune-boosting drugs help your body's own immune system attack the cancer from another angle.
You likely qualify if…
You likely don't qualify if…
You would receive one or two injections of the new medication spaced according to your assigned group, followed by standard immune therapy pills or infusions. Throughout treatment and follow-up, you'll have regular blood tests, imaging scans to measure your tumor response, and visits to monitor for side effects. The study tracks how the medication moves through your body, the radiation dose you receive, and how well it works against your cancer over several months.
AI-generated summary from trial data · Aug 1, 2026 · Not medical advice
China